Nanomedicine: real commercial potential or just hype? by Webster, Thomas J
373 International Journal of Nanomedicine 2006:1(4) 373–374
© 2006 Dove Medical Press Limited.  All rights reserved
EDITORIAL FOREWORD
Volume 1 • Number 4 • 2006
Thomas J Webster
Divisions of Engineering and 




Nanomedicine: real commercial potential or  
just hype?
What is the real commercial potential for nanotechnology and, in particular, 
nanomedicine? Depends on your definition. For example, if you think nanomedicine 
refers to Michael Crichton’s self-replicating nanorobots traversing the body and healing 
disease (as in his 2002 novel Prey), I bet you will be waiting a long time (if ever) to 
see commercial fruition. On the other hand, if you envision nanomedicine as listening 
to meditation music from your iPod nano (and, thus, healing your soul), then you are 
in luck as you are already experiencing commercial benefits of nanomedicine. If only 
you had bought the stock. 
But if you are like the rest of us with a more reasonable interpretation of 
nanomedicine (the use of nanomaterials in medicine), you are somewhere in between. 
While it can be stated that medical fields (such as implants, imaging, diagnostics, drug 
delivery, etc) are experiencing varying degrees of nanomedicine success, it is safe to 
say they all are beginning to see commercialization. Products have emerged. These 
include various nanomaterials (nanoparticles, nanotubes, nanostructured materials, and 
nanocomposites), nanotools (nanolithography tools and scanning probe microscopes), 
and nanodevices (nanosensors and nanoelectronics) which are available commercially, 
some for human use. To some this may not sound significant, but consider for a 
moment the time span numerous government agencies around the world require for 
a new medical device for human use. When considering that new pharmaceuticals 
require up to 15 years of testing to get through the approval process (and this is just 
one example), it is clearly a significant advancement to even have nanomedicine 
products on the market.
Certainly, though, the promise of nanotechnology has created lofty expectations 
in some quarters. The expectations continue to grow from year to year. For example, 
the US National Science Foundation (as one example) has contributed to this hype. 
The US National Science Foundation is on record as predicting that the market for 
nanotechnology, or products containing nanotechnology, will reach US$1 trillion in 
10–15 years (http://www.biz-lib.com). Clearly, medical products will be a significant 
part of this expectation. With any new technology, both advocates and opponents of 
nanotechnology tend to lose sight of the fact that progress in developing commercial 
nanotechnology applications has been understandably slow to date, but the excitement 
is still as high (if not higher) than when nanomedicine emerged over 10 years ago. 
Importantly too, expectations for nanomedicine remain high. The expected 
commercial potential has not decreased or even remained the same over the past 
decade, but has only increased. Some have predicted that nanomedicine will exhibit 
strong growth in all sectors until as far out as 2011, leading to multi-billion dollar 
revenues (http://www.piribo.com). Key nanomedicine technology platforms (such 
as nanocrystals, nanotubes, dendrimers, fullerenes, quantum dots, and molecular 
scaffolding) are expected to drive that market expansion (http://www.piribo.com). Few 
research fields have been able to sustain and grow such excitement that continues to 
drive nanomedicine.
So while in business and academia we are perpetually thinking of the future and 
asking what is the real commercial potential of nanomedicine, we should not forget International Journal of Nanomedicine 2006:1(4) 374
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about where we have come. (After all, the worldwide market 
for nanoscale devices was US$406 million in 2002 [http://
www.bccresearch.com/editors/RB-162.html]). Here, it is safe 
to say, that we have already met one important expectation: 
we have created products based on nanomedicine principles. 
Whether we will meet the continually increasing expectations 
of nanomedicine remains to be seen, but it is clear we have 
passed a significant milestone already that should put this 
question to rest.
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